HOME
• effexor nightmares
• compare effexor and cymbalta
• migraine and effexor
• effexor dog

dosage for effexor

Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic dosage for effexor trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself. U.S. U.S. Contact your doctor right away if this happens. Cases with serum sodium lower than 110 mmol/L have been reported.

Go To...

• good things about effexor
• menopause effexor
• prozac taken together with 25mg effexor
• advisability of effexor xr
• does effexor xr cause weight gain

dosage for effexor

Hyponatremia tends to develop within the first few weeks of treatment (range 3 to 120 days) dosage for effexor typically resolves within 2 weeks (range 48 hours to 6 weeks) after therapy has been discontinued with some patients requiring treatment. There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy. Top Side Effects by Body System Gastrointestinal Gastrointestinal side effects have frequently included nausea (up to 35%), dry mouth (14% to 18%), constipation (12%), anorexia (12% to 23%), vomiting, diarrhea (5% to 12%), eructation, abdominal pain, and flatulence. Gastrointestinal side effects reported in premarketing Phase 3 trials have included increased appetite, dosage for effexor colitis, dysphagia, tongue edema, esophagitis, gastritis, gastroenteritis, gastrointestinal ulcer, gingivitis, glossitis, rectal hemorrhage, hemorrhoids, melena, dosage for effexor moniliasis, stomatitis, mouth ulceration, abdominal distention, biliary pain, cheilitis, cholecystitis, cholelithiasis, esophageal spasms, duodenitis, hematemesis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gum hemorrhage, hepatitis, ileitis, jaundice, intestinal obstruction, liver dosage for effexor parotitis, periodontitis, proctitis, rectal disorder, salivary gland enlargement, increased salivation, soft stools, and tongue discoloration. Nervous system Nervous system side effects have frequently included dizziness (16%), somnolence (up to 14%), insomnia (11% to 25%), fatigue (11%), nervousness (9%), abnormal dreams, sleep abnormalities, tremor, depression, paresthesia, decreased libido, agitation, hypertonia, anxiety, delirium, and twitching. Dyskinesia has also been reported. Venlafaxine has been reported to increase the pain tolerance threshold to electrical sural nerve stimulation and the threshold at which pain increases (pain summation). One case of serotonin syndrome has been reported which is believed to have been precipitated by the combination of venlafaxine and trazodone. One small study has suggested dosage for effexor venlafaxine may improve attention, concentration, memory, and reaction time performance after single oral doses. Nervous system side effects reported in premarketing Phase 3 trials have included amnesia, confusion, depersonalization, hypesthesia, abnormal thinking, trismus, vertigo, akathisia, apathy, ataxia, circumoral paresthesia, central nervous system (CNS) stimulation, hostility, hyperesthesia, hyperkinesia, hypotonia, incoordination, myoclonus, neuralgia, neuropathy, seizure, abnormal speech, stupor, adjustment disorder, akinesia, alcohol abuse, aphasia, bradykinesia, buccoglossal syndrome, cerebrovascular accident, feeling drunk, loss of consciousness, dementia, dystonia, increased energy, facial paralysis, abnormal gait, Guillain-Barre Syndrome, hyperchlorhydria, hypokinesia, hysteria, dosage for effexor control difficulties, increased libido, motion sickness, neuritis, nystagmus, paresis, decreased or increased reflexes, and torticollis. However, there is a dose dependency for blood pressure increase. Laboratory Changes Of the serum chemistry and hematology parameters monitored during clinical trials with Effexor, a statistically significant difference with placebo was seen only for serum cholesterol. Although these events occurred during treatment with venlafaxine, causality has not been determined. Experience with the immediate-release venlafaxine showed that sustained hypertension was dose-related, increasing from 3% to 7% at 100 to 300 mg/day to 13% at doses above 300 mg/day. Although these events occurred during treatment with venlafaxine, causality has not been determined. There is a single case report of breast pain associated with venlafaxine therapy. Dermatologic At least 3 cases of venlafaxine- induced alopecia have been reported. Withdrawal symptoms were reported to include brief bursts of dizziness associated with headache, anxiety, irritability, agitation, insomnia, paresthesias, nausea, vomiting, diarrhea, tremor, fatigue, sweating, and worsening of depression (similar to symptoms reported after withdrawal from selective serotonin reuptake inhibitors). Following discontinuation of therapy the amount of REM sleep tends to rebound. Symptoms resolved following discontinuation of therapy. Genitourinary side effects have frequently included male and female sexual dysfunction such as abnormal ejaculation in up to 16% of male patients, decreased libido (13%), impotence (13%), and organic dysfunction (anorgasmia or abnormal orgasm) in up to 8% of female patients. Genitourinary side effects reported in premarketing Phase 3 trials have included prostatic disorder (prostatitis, enlarged prostate, and prostate irritability), impaired urination, albuminuria, amenorrhea, cystitis, dysuria, hematuria, leukorrhea, menorrhagia, metrorrhagia, nocturia, breast pain, polyuria, urinary incontinence, urinary retention, urinary urgency, vaginal hemorrhage, vaginitis, abortion, anuria, breast discharge, breast engorgement, balanitis, breast enlargement, endometriosis, female lactation, fibrocystic breast, calcium crystalluria, cervicitis, orchitis, ovarian cyst, bladder pain, prolonged erection, gynecomastia (male), hypomenorrhea, mastitis, menopause, oliguria, salpingitis, urolithiasis, uterine hemorrhage, uterine spasm, and vaginal dryness. Although these events occurred during treatment with venlafaxine, causality has not been determined. Respiratory Respiratory side effects have frequently included pharyngitis, sinusitis, and yawning. Respiratory side effects reported in premarketing Phase 3 trials have included increased cough, dyspnea, asthma, chest congestion, epistaxis, hyperventilation, laryngismus, laryngitis, pneumonia, voice alteration, atelectasis, hemoptysis, hypoventilation, hypoxia, larynx edema, pleurisy, pulmonary embolus, and sleep apnea. In the event that therapy is not reintroduced, withdrawal symptoms may last from 5 to 7 days before resolving spontaneously. In one case report, withdrawal- induced full mania developed in a 33- year- old patient following abrupt termination of treatment with venlafaxine extended-release (150 mg daily for 10 weeks). Hepatic Hepatic side effects have included toxic hepatitis. In a flexible-dose study, with doses in the range of 200 to 375 mg/day and mean dose greater than 300 mg/day, the mean pulse was increased by about 2 beats per minute compared with a dosage for effexor of about 1 beat per minute for placebo. In controlled clinical dosage for effexor Effexor was associated with mean increases in diastolic blood pressure ranging from dosage for effexor to 2.5 mm Hg averaged over all dose groups, compared to mean decreases ranging from 0.9 to 3.8 mm Hg for placebo. Angle-closure glaucoma has been reported rarely. Ocular side effects reported in premarketing Phase 3 trials have included abnormality of accommodation, mydriasis, conjunctivitis, diplopia, dry eyes, eye pain, photophobia, visual field defect, blepharitis, cataract, chromatopsia, conjunctival edema, corneal lesion, exophthalmos, eye hemorrhage, glaucoma, retinal hemorrhage, subconjunctival hemorrhage, keratitis, miosis, papilledema, decreased pupillary reflex, scleritis, and uveitis. Following discontinuation of venlafaxine, symptoms resolved within approximately 72 hours. Symptoms resolved following discontinuation of therapy. Genitourinary side effects have frequently included male and female sexual dysfunction such as abnormal ejaculation in up to 16% of male patients, decreased libido (13%), impotence (13%), and organic dysfunction (anorgasmia or abnormal orgasm) in up to 8% of female patients. Genitourinary side effects reported in premarketing Phase 3 trials have included prostatic disorder (prostatitis, enlarged prostate, and prostate irritability), impaired urination, albuminuria, amenorrhea, cystitis, dysuria, hematuria, leukorrhea, menorrhagia, metrorrhagia, nocturia, breast pain, polyuria, urinary incontinence, urinary retention, urinary urgency, vaginal hemorrhage, vaginitis, abortion, anuria, breast discharge, breast engorgement, balanitis, breast enlargement, endometriosis, female lactation, fibrocystic breast, calcium crystalluria, cervicitis, orchitis, ovarian cyst, bladder pain, prolonged erection, gynecomastia (male), hypomenorrhea, mastitis, menopause, oliguria, salpingitis, dosage for effexor uterine hemorrhage, uterine spasm, and vaginal dryness. Although these events occurred during treatment with venlafaxine, causality has not been determined. There have been a minimum of approximately fifteen cases of hyponatremia in which at least one was life threatening, including at least one case of recurrent venlafaxine- induced hyponatremia after rechallenge. A recent short-term study dosage for effexor weeks) has reported an average weight loss of 2 to 3 pounds in patients treated with venlafaxine. Numerous cases of hyponatremia have been reported following treatment with a selective serotonin reuptake inhibitor (SSRI). Tachycardia and QTc prolongation appear to occur in a dose-dependent manner. In one case report, venlafaxine (75 mg 3 times/day) may have contributed to an elevation in defibrillation threshold in dosage for effexor patient with nonischemic cardiomyopathy and an implantable cardioverter- defibrillator. dosage for effexor a flexible-dose study, with doses in the range of 200 to 375 mg/day and mean dose greater than 300 mg/day, the mean change in heart rate was 8.5 beats per minute compared with 1.7 beats per minute for placebo. Other Events Observed During the Premarketing Evaluation of Venlafaxine During its premarketing assessment, multiple doses of Effexor were administered to 2897 patients in Phase 2 and Phase 3 studies.